The gene therapy regimen seems to be working wonders, including restoring nearly all hearing to a seven-year-old patient ...

While gene therapy clinical trials for peripheral artery disease ( PAD) using plasmid DNA or adenoviral vectors show no clear benefit in amputation-free survival, amputation, and all-cause mortality, ...

Bioluminescent imaging is helping researchers better understand the effectiveness of tissue regeneration enhancers delivered to injured heart tissue by different adeno-associated virus vectors.

JCR Pharmaceuticals has signed a licence agreement with Alexion, AstraZeneca Rare Disease, for its proprietary JUST-AAV ...

AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...

Since its isolation, the biological properties of the adeno-associated virus have been increasingly understood, improving our ability to manipulate and use it as a safe and efficient gene therapy ...